

PAD INTERVENTIONAL MARKET ANALYSIS BASED ON TREATMENT WITH ANGIOPLASTY OR ATHERECTOMY

References (First and Last Pages)

1. Nowygrod R, Egorova N, Grecco G, et al. Trends, complications, and mortality in peripheral vascular surgery. *J Vasc Surg* 2006; 43: 205-16.
2. Murphy TP, Soares G, Kim M. Increase in utilization of percutaneous renal artery interventions by Medicare beneficiaries, 1996-2000. *AJR* 2004; 183: 561-8.
3. Balk E, Raman G, Chung M, et al. Comparative effectiveness of management strategies for renal artery stenosis. Comparative effectiveness review No. 5. (Prepared by Tufts-New England Medical Center Evidence-based Practice center under contract No. 290-02-0022.) Rockville, MD: Agency for Healthcare Research and Quality. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm.
4. Yost ML. Acute limb ischemia. A market of multiple therapies and multiple procedures. Atlanta (GA): THE SAGE GROUP; 2005.
5. HCUPnet, Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality, Rockville, MD. [Internet]. Available at <http://www.hcup.ahrq.gov/>
6. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. *Lancet* 2005; 366: 1925-34.
7. Allie DE, Hebert CJ, Lirtzman MD, et al. Critical limb ischemia: a global epidemic. A critical analysis of current treatment unmasks the clinical and economic costs of CLI. *Eurointervention* 2005; 1(1): 60-69.
8. Hallett JW, Byrne J, Gayari MM, et al. Impact of arterial surgery and balloon angioplasty on amputation: a population-based study of 1155 procedures between 1973 and 1992. *J Vasc Surg* 1997; 25: 29-38.
9. Allie DE. The global impact of CLI in 2006. "The Rutherford Class VII patient." Presentation at Multidisciplinary International CLI Summit 2006, Nov 2; New Orleans, LA.
10. Yost ML. Peripheral arterial disease underestimated, underdiagnosed and undertreated. Volume II: A significant opportunity for interventional therapies. Atlanta (GA): THE SAGE GROUP; 2004.
11. McIntyre KE. Aortoiliac occlusive disease. Continuing Medical Education (CME) article on the e-medicine website. [Cited 2002]. Available at <http://www.emedicine.com/med/topic2759.htm>
12. Gray BH. Endovascular treatment of peripheral arterial disease. *J Am Osteopath Assoc*. 2000; 100(10 Su Pt 2): S15-20.

40. Yost ML. Critical limb ischemia. Volume II. Western Europe. Prevalence, market opportunities and analysis of the most common comorbidity: diabetes. Atlanta (GA): THE SAGE GROUP; 2007.
41. Yost ML. Physician specialties involved in the diagnosis and management of peripheral arterial disease. Analysis of numbers and characteristics. Atlanta (GA): THE SAGE GROUP; 2006.
42. Schillinger M, Sabeti S, Dick P, et al. Sustained benefit at 2 years of primary femoropopliteal stenting with balloon angioplasty with optional stenting. *Circulation* 2007; 115: 2745-2749.
43. Bosiers M, Deloose K, Verbist J, Peeters P. Nitinol stenting for treatment of "below-the-knee" critical limb ischemia: 1-year angiographic outcome after Xpert stent implantation. *J Cardiovasc Surg (Torino)*. 2007; 48(4):455-61.
44. Ansel GM. Stents (grafting) should be the primary treatment for symptomatic superficial femoral artery disease. *Catheter Cardiovasc Interv*. 2007; 69(6):886-9.
45. SFA Stenting Studies. *Endovascular Today* 2007; 6(6): 66.
46. Scheinert DS, Biamino G, Schmidt AJ. Preliminary experience with DESs in tibial arteries. *Endovascular Today* 2006; 5(7): 60-2.
47. Bosiers M, Deloose K, Verbist J, Peeters P. First clinical application of absorbable metal stents in the treatment of critical limb ischemia: 12-month results. *Vascular Disease Management* 2005; 2(4): 86-91.
48. Fischer M, Schwabe C, Schulte KL. Value of the hemobahn/viabahn endoprosthesis in the treatment of long chronic lesions of the superficial femoral artery: 6 years of experience. *J Endovasc Ther*. 2006; 13(3):281-90.
49. Kickuth R, Keo HH, Triller J, Ludwig K, Do DD. Initial clinical experience with the 4-F self-expanding XPERT stent system for infrapopliteal treatment of patients with severe claudication and critical limb ischemia. *J Vasc Interv Radiol*. 2007; 18(6):703-8.
50. Siablis D, Karnabatidis D, Katsanos K, Kagadis GC, et al. Sirolimus-eluting versus bare stents after suboptimal infrapopliteal angioplasty for critical limb ischemia: enduring 1-year angiographic and clinical benefit. *J Endovasc Ther*. 2007; 14(2):241-50.
51. Smouse HB. Drug-eluting stents in the periphery. A summary of barriers, unanswered questions, and potential benefits of this technology. *Endovascular Today* 2007; 6(6): 72-74.
52. Scheinert D, Scheinert S, Sax J, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. *J Am Coll Cardiol* 2005; 45: 312-5.
53. Yost ML. Peripheral arterial disease. Endovascular market analysis by vascular territory. Atlanta (GA): THE SAGE GROUP; 2006.